URI Ryan Institute Joins Forces with Banner Alzheimer’s Institute
FEBRUARY 27, 2018
The University of Rhode Island’s George & Anne Ryan Institute for Neuroscience has joined forces with the esteemed Banner Alzheimer’s Institute in a partnership that increases the reach and impact of efforts at both institutes to find new treatments for Alzheimer’s disease and support for caregivers.
The first focus of the partnership is boosting enrollment in the Alzheimer’s Prevention Registry, hosted by Banner’s Alzheimer’s Institute. The Alzheimer’s Prevention Registry is a national registry of more than 290,000 adults age 18 and older who are interested in learning about studies on Alzheimer’s research and prevention in their community. Any adult can join for free at ryaninstitute.uri.edu.
“There are critical advancements being made in Alzheimer’s research, but they depend on volunteers who are willing to participate in a study or trial.”
“We are proud to work with Banner Alzheimer’s Institute and the Alzheimer’s Prevention Registry to connect Rhode Islanders with important Alzheimer’s clinical studies and trials happening where they live,” said Paula Grammas, executive director of the Ryan Institute and Thomas M. Ryan Professor of Neuroscience. “There are critical advancements being made in Alzheimer’s research, but they depend on volunteers who are willing to participate in a study or trial. We see a great potential to help address this need in Rhode Island, and to benefit individuals and families affected by Alzheimer’s disease.”
People who join the Alzheimer’s Prevention Registry will be notified about any studies for which they may qualify. Many studies research lifestyle choices such as diet and exercise, or can be completed online. A portion are trials of investigational drug treatments.
A Meaningful Partnership for Rhode Islanders
“The Ryan Institute is committed to outreach efforts that empower the community in the fight against neurodegenerative disease,” said Grammas. “This partnership is not only a meaningful next step in that mission but also paves the way for future research collaborations and innovation.”
Based in Phoenix, Arizona, the Banner Alzheimer’s Institute is an internationally-known care and research center for individuals and families affected by Alzheimer’s and is a world leader in brain imaging research. Banner Alzheimer’s Institute is part of Banner Health, among the largest nonprofit health care systems in the country.
“Nearly 80 percent of studies fail to meet their recruitment goals,” said Jessica Langbaum, director of the Alzheimer’s Prevention Registry and principal scientist at Banner Alzheimer’s Institute. “We are excited to partner with Ryan Institute to connect Rhode Islanders to groundbreaking research studies taking place in their community.”
About Banner Alzheimer’s Institute
Through its research and care, Banner Alzheimer’s Institute is dedicated to the goal of ending Alzheimer’s disease without losing another generation. Founded in 2006 by Banner Health, one of the country’s largest nonprofit health care systems, BAI has a three-fold focus: to conduct revolutionary studies in the detection, treatment and prevention of Alzheimer’s; to set a national standard of patient and family care; and to forge scientific collaborations that bring together institutions and disciplines internationally.
About Alzheimer’s Prevention Initiative
The Alzheimer’s Prevention Initiative (API) is an international collaborative formed to launch a new era of Alzheimer’s prevention research. Led by the Banner Alzheimer’s Institute, the API will conduct prevention trials in cognitively healthy people at increased genetic risk for Alzheimer’s disease. It will continue to establish the brain imaging, biological and cognitive measurements needed to rapidly test promising prevention therapies and provide registries to support enrollment in future prevention trials. API is intended to provide the scientific means, accelerated approval pathway and enrollment resources needed to evaluate the range of promising Alzheimer’s prevention therapies and find ones that work without losing another generation.